Goadsby spoke about differentiating between the foursome of preventive therapies soon to be available to physicians.
“At the moment, happily, as long as you can learn to use one, you’re going to do a lot of good.”
By mid-September, patients with chronic and episodic migraine and the physicians that treat them may be able to, for the first time, have choices between preventive agents.
With erenumab already on the market, galcanezumab and fremanezumab set to soon join it, and eptinezumab not far behind, the future is bright in migraine, according to Peter J. Goadsby, MD, PhD, DSc, a professor of neurology at both the University of California San Francisco and King’s College, London, as well as the director of the NIHR-Wellcome Trust Clinical Research Facility at King’s College Hospital and the Chair of the British Association for the Study of Headache. He spoke with NeurologyLive in an interview to discuss differentiating between the foursome.
Goadsby also spoke about the new class of acute therapies, the gepants, which have advanced the treatment paradigm in acute migraine care by lacking vasoconstriction properties. Although they show a strong safety profile and appear efficacious, how they will intertwine into the state of care with the calcitonin gene-related peptide inhibitors remains to be seen.